Autopsy report · NCT00480025

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

“The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 7 years before it stopped.
• 2,278 participants enrolled.
• Results were posted on the registry 4 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Lung Cancer, Non-Small Cell

Interventions

GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Placebo Control

Participants

2,278

Sites

620

Countries

Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Estonia, Finland, France, Germany and more

Trials that died the same way

• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (83% match in meaning)
• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (83% match in meaning)
• A Study of LY3405105 in Participants With Advanced Cancer
  “The study was terminated for lack of sufficient efficacy.” (82% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (82% match in meaning)
• A Study of Tadalafil for Duchenne Muscular Dystrophy
  “The study is being terminated for lack of efficacy” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.